Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 1
1963 1
1965 4
1967 3
1969 2
1970 1
1971 3
1972 1
1973 2
1974 1
1977 2
1978 5
1979 2
1980 1
1981 4
1982 1
1984 3
1985 3
1988 3
1989 3
1990 3
1991 8
1992 8
1993 4
1994 8
1995 7
1996 6
1997 11
1998 29
1999 32
2000 44
2001 50
2002 40
2003 50
2004 48
2005 51
2006 49
2007 55
2008 56
2009 52
2010 70
2011 62
2012 66
2013 75
2014 53
2015 70
2016 70
2017 55
2018 69
2019 93
2020 86
2021 80
Text availability
Article attribute
Article type
Publication date

Search Results

1,380 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Nurnaeimah
Page 1
Targeting NF-kappaB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer.
Pflug KM, Sitcheran R. Pflug KM, et al. Int J Mol Sci. 2020 Nov 11;21(22):8470. doi: 10.3390/ijms21228470. Int J Mol Sci. 2020. PMID: 33187137 Free PMC article. Review.
As such aberrant expression or regulation of NIK is associated with several disease states. For example, loss of NIK leads to severe immune defects, while the overexpression of NIK is observed in inflammatory diseases, metabolic disorders, and the development …
As such aberrant expression or regulation of NIK is associated with several disease states. For example, loss of NIK leads to …
Non-canonical NF-κB signaling pathway.
Sun SC. Sun SC. Cell Res. 2011 Jan;21(1):71-85. doi: 10.1038/cr.2010.177. Epub 2010 Dec 21. Cell Res. 2011. PMID: 21173796 Free PMC article. Review.
A unique mechanism of NIK regulation is through its fate control: the basal level of NIK is kept low by a TRAF-cIAP destruction complex and signal-induced non-canonical NF-kappaB signaling involves NIK stabilization. Tight control of the fate of NIK is …
A unique mechanism of NIK regulation is through its fate control: the basal level of NIK is kept low by a TRAF-cIAP destructio …
The noncanonical NF-κB pathway.
Sun SC. Sun SC. Immunol Rev. 2012 Mar;246(1):125-40. doi: 10.1111/j.1600-065X.2011.01088.x. Immunol Rev. 2012. PMID: 22435551 Free PMC article. Review.
Under normal conditions, NIK is targeted for continuous degradation by a tumor necrosis factor (TNF) receptor-associated factor-3 (TRAF3)-dependent E3 ubiquitin ligase. In response to signals mediated by a subset of TNF receptor superfamily members, NIK becomes stab …
Under normal conditions, NIK is targeted for continuous degradation by a tumor necrosis factor (TNF) receptor-associated factor-3 (TR …
NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis.
Jie Z, Yang JY, Gu M, Wang H, Xie X, Li Y, Liu T, Zhu L, Shi J, Zhang L, Zhou X, Joo D, Brightbill HD, Cong Y, Lin D, Cheng X, Sun SC. Jie Z, et al. Nat Immunol. 2018 Nov;19(11):1224-1235. doi: 10.1038/s41590-018-0206-z. Epub 2018 Sep 24. Nat Immunol. 2018. PMID: 30250187 Free PMC article.
NIK-activated noncanonical NF-kappaB induced expression of IL-23 in DCs, contributing to the maintenance of T(H)17 cells and type 3 ILCs. Consistent with the dual functions of IL-23 and IL-17 in mucosal immunity and inflammation, NIK deficiency also ameliorated coli
NIK-activated noncanonical NF-kappaB induced expression of IL-23 in DCs, contributing to the maintenance of T(H)17 cells and type 3 I
NIK as a Druggable Mediator of Tissue Injury.
Valiño-Rivas L, Vaquero JJ, Sucunza D, Gutierrez S, Sanz AB, Fresno M, Ortiz A, Sanchez-Niño MD. Valiño-Rivas L, et al. Trends Mol Med. 2019 Apr;25(4):341-360. doi: 10.1016/j.molmed.2019.02.005. Epub 2019 Mar 26. Trends Mol Med. 2019. PMID: 30926358 Review.
The spectrum of NIK-associated disease now ranges from immunodeficiency (when NIK is defective) to autoimmunity, cancer, sterile inflammation, fibrosis, and metabolic disease when NIK is overactive. The development of novel small-molecule NIK inhibitor …
The spectrum of NIK-associated disease now ranges from immunodeficiency (when NIK is defective) to autoimmunity, cancer, steri …
MAP3K kinases and kidney injury.
Cuarental L, Sucunza-Sáenz D, Valiño-Rivas L, Fernandez-Fernandez B, Sanz AB, Ortiz A, Vaquero JJ, Sanchez-Niño MD. Cuarental L, et al. Nefrologia (Engl Ed). 2019 Nov-Dec;39(6):568-580. doi: 10.1016/j.nefro.2019.03.004. Epub 2019 Jun 10. Nefrologia (Engl Ed). 2019. PMID: 31196660 Free article. Review. English, Spanish.
There is in vivo interventional evidence clearly supporting a role for MAP3K5 (ASK1) and MAP3K14 (NIK) in the pathogenesis of experimental kidney disease. Indeed, the ASK1 inhibitor Selonsertib has undergone clinical trials for diabetic kidney disease. ...
There is in vivo interventional evidence clearly supporting a role for MAP3K5 (ASK1) and MAP3K14 (NIK) in the pathogenesis of experim …
NIK inhibitor impairs chronic periodontitis via suppressing non-canonical NF-kappaB and osteoclastogenesis.
Wang J, Wang B, Lv X, Wang L. Wang J, et al. Pathog Dis. 2020 Oct 7;78(7):ftaa045. doi: 10.1093/femspd/ftaa045. Pathog Dis. 2020. PMID: 32860691
Blocking NIK activity also resulted in reduced osteoclasts specific genes expression and enhanced IFN-beta expression. ...Application of NIK-SMI1 may serve as a potential therapeutic approach for periodontitis....
Blocking NIK activity also resulted in reduced osteoclasts specific genes expression and enhanced IFN-beta expression. ...Application …
1,380 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page